Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Hum Cell ; 37(5): 1567-1577, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38980565

RESUMO

The neurometabolic disorder known as biotin-thiamine-responsive basal ganglia disease (BTBGD) is a rare autosomal recessive condition linked to bi-allelic pathogenic mutations in the SLC19A3 gene. BTBGD is characterized by progressive encephalopathy, confusion, seizures, dysarthria, dystonia, and severe disabilities. Diagnosis is difficult due to the disease's rare nature and diverse clinical characteristics. The primary treatment for BTBGD at this time is thiamine and biotin supplementation, while its long-term effectiveness is still being investigated. In this study, we have generated two clones of induced pluripotent stem cells (iPSCs) from a 10-year-old female BTBGD patient carrying a homozygous mutation for the pathogenic variant in exon 5 of the SLC19A3 gene, c.1264A > G (p.Thr422Ala). We have confirmed the pluripotency of the generated iPS lines and successfully differentiated them to neural progenitors. Because our understanding of genotype-phenotype correlations in BTBGD is limited, the establishment of BTBGD-iPSC lines with a homozygous SLC19A3 mutation provides a valuable cellular model to explore the molecular mechanisms underlying SLC19A3-associated cellular dysfunction. This model holds potential for advancing the development of novel therapeutic strategies.


Assuntos
Doenças dos Gânglios da Base , Homozigoto , Células-Tronco Pluripotentes Induzidas , Mutação de Sentido Incorreto , Humanos , Doenças dos Gânglios da Base/genética , Feminino , Mutação de Sentido Incorreto/genética , Criança , Tiamina , Proteínas de Membrana Transportadoras/genética , Diferenciação Celular/genética , Arábia Saudita , Linhagem Celular , Estudos de Associação Genética , Biotina
2.
Stem Cell Res ; 71: 103158, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37406498

RESUMO

Myoglobin (MB) is a cytoplasmic hemoprotein that is predominantly expressed in the heart and oxidative myofibers of skeletal muscle. It has been demonstrated that MB binds to oxygen and promotes its diffusion for energy production in the mitochondria. Recently, MB was found to be expressed in different forms of malignant tumors and cancer cell lines. Further studies using gene disruption technology will enhance the understanding of MB's role in human cardiovascular biology and cancers. Here, we describe the generation of a homozygous MB knockout in human embryonic stem cells (hESC-MB-/-) via CRISPR/Cas9 to study MB function in human biology and diseases.


Assuntos
Células-Tronco Embrionárias Humanas , Mioglobina , Humanos , Mioglobina/genética , Mioglobina/metabolismo , Células-Tronco Embrionárias Humanas/metabolismo , Sistemas CRISPR-Cas/genética , Linhagem Celular , Tecnologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa